Market capitalization | $10.00k |
Enterprise Value | $4.34m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.45 |
P/S ratio (TTM) P/S ratio | 0.00 |
P/B ratio (TTM) P/B ratio | 0.00 |
Revenue growth (TTM) Revenue growth | -7.53% |
Revenue (TTM) Revenue | $9.61m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast ThermoGenesis Holdings Inc:
1 Analyst has issued a forecast ThermoGenesis Holdings Inc:
Mar '24 |
+/-
%
|
||
Revenue | 9.61 9.61 |
8%
8%
|
|
Gross Profit | 2.03 2.03 |
30%
30%
|
|
EBITDA | -4.87 -4.87 |
2%
2%
|
EBIT (Operating Income) EBIT | -6.09 -6.09 |
1%
1%
|
Net Profit | -15 -15 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It operates through the Device and Clinical Development segment. The Device segment includes the development and commercialization of automated technologies for cell-based therapeutics and bioprocessing. The Clinical Development segment utilizes autologous stem cell-based therpeutics. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.
Head office | United States |
CEO | Xiao Xu |
Employees | 25 |
Founded | 1986 |
Website | www.thermogenesis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.